PetVivo Holdings Inc. is a biomedical device company dedicated to developing, manufacturing, and commercializing innovative medical devices and therapeutics for companion animals. The company's primary focus is on advancing solutions for veterinary medicine, particularly in the management of joint-related conditions such as lameness and osteoarthritis in dogs, cats, and horses. A key product in its portfolio is Spryng, a veterinarian-administered, intra-articular injectable that leverages proprietary micro-cushion technology to address missing or damaged cartilage, offering a solution that targets the underlying causes of joint pain rather than simply masking symptoms. PetVivo maintains a robust pipeline of therapeutic devices, some of which are being adapted for potential human clinical applications. The company holds a significant intellectual property portfolio with over 20 patents covering its biomaterials, production processes, and product applications. Operating from an ISO 7 certified clean room manufacturing facility in Minneapolis, PetVivo aims to advance animal health through innovation, impacting the broader animal healthcare and biomedical device sectors.